Research Profile — Weight Loss Research

Tesamorelin: GHRH Analog Research Profile

TH9507Trans-3-hexenoic acid modified GHRH analog

Tesamorelin is a modified GHRH analog most often discussed in metabolic research due to data showing effects on visceral adipose tissue and body-composition metrics. It is used as a pathway-specific comparator against shorter GHRH analogs and ghrelin-pathway secretagogues when protocols require endocrine-metabolic crossover interpretation.

Technical Specifications

CAS Number	218949-48-5
Molecular Formula	C221H366N72O67S
Molecular Weight	5135.88 g/mol
Amino Acids	44
Sequence	44-amino-acid GHRH analog with trans-3-hexenoic acid modification
Purity	>=99% (HPLC)
Appearance	White lyophilized powder
Salt Form	Acetate
Solubility	Soluble in water
Storage	-20C lyophilized, 2-8C reconstituted

Origin & Discovery

Tesamorelin is a stabilized GHRH analog developed for endocrine and metabolic applications where pituitary GH-axis activation and body-composition endpoints are of interest.

Mechanism of Action

Tesamorelin stimulates pituitary GH release through GHRH receptor activation with design features intended to improve stability. GHRH Pathway Entry: Activates pituitary somatotroph signaling and downstream IGF-1 trends. Metabolic Endpoint Relevance: Frequently evaluated against visceral adiposity and body composition outcomes. Comparator Position: Used in studies comparing GHRH analog classes with other GH-axis signaling approaches.

Visceral Adipose Tissue Studies

Clinical research has evaluated tesamorelin for effects on visceral adipose tissue and related metabolic markers, making it one of the better-characterized GHRH analogs for body-composition endpoints.

Citations

Falutz J, et al. (2010) "Tesamorelin treatment and changes in visceral adipose tissue." N Engl J Med, 363(26), 2552-2563.

Endocrine-Metabolic Cross-Interpretation

Tesamorelin is often used to examine how GH-axis modulation intersects with metabolic outcomes over medium- to long-duration protocols, including adiposity and liver-related biomarker contexts.

Citations

Stanley TL, et al. (2014) "Tesamorelin and metabolic/liver endpoint investigations." JAMA, 312(4), 380-389.

Frequently Asked Questions

What is tesamorelin?▼

Tesamorelin is a stabilized GHRH analog studied for GH-axis signaling and body-composition outcomes, especially visceral adipose tissue contexts.

How does tesamorelin differ from sermorelin?▼

Both are GHRH-pathway compounds, but tesamorelin has distinct molecular modifications and is often discussed in relation to visceral fat endpoint data.

Can tesamorelin be compared with ipamorelin?▼

Yes. This comparison is common because tesamorelin is GHRH-pathway based, while ipamorelin is ghrelin-receptor-pathway based.